Stage | Treatment | N | 0 | 1 | 1.5 | 2 | 2.5 | Average |
---|
PRO | Saline | 5 | 5 | | | | | 0.0 |
DOX | 5 | 1 | 1 | 2 | 1 | | 1.2 |
DOX + DRZ | 5 | 1 | 2 | 2 | | | 1.0 |
EST | Saline | 5 | 1 | 4 | | | | 0.8 |
DOX | 5 | 1 | 1 | 3 | | | 1.1 |
DOX + DRZ | 5 | 1 | 2 | 1 | 1 | | 1.1 |
MET | Saline | 5 | 2 | 3 | | | | 0.6 |
DOX | 5 | 1 | 1 | 1 | 2 | | 1.3 |
DOX + DRZ | 5 | 1 | 2 | 2 | | | 1.0 |
DIE | Saline | 5 | 3 | 2 | | | | 0.4 |
DOX | 5 | | | 1 | 2 | 2 | 2.1 |
DOX + DRZ | 5 | | | 4 | 1 | | 1.6 |
- Histopathology of cardiac sections from the SHRs at day 12 was assessed for cardiomyocyte lesions (myofibrillar loss and vacuolization) by a board-certified pathologist. The cardiomyopathy or lesion score indicates the percentage of affected cardiomyocytes within the sampled heart section: 0 is no observed change, 1 is < 5%, 1.5 is 5–15%, 2 is 16–25%, 2.5 is 26–35%, and 3 is > 35%